Renal Cancer Drugs Market will reach $5.6bn in 2019, according to new visiongain data

LONDON - Jan. 26, 2016 - PRLog -- Renal cancer drugs market will reach $5.6bn in 2019, according to new visiongain data

A new study by visiongain forecasts the world kidney cancer treatments industry will achieve revenues of $5.6 billion in 2019. Those sales will expand from 2015 to 2025 as the loss of market exclusivity is compensated for by launches of new therapies. That revenue forecast and others appear in Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025. Visiongain published that report in October 2015.

Visiongain’s investigation analyses events, prospects and sales opportunities shaping the development and production of drug treatments for renal cancer. That work shows multilevel revenue forecasting and qualitative analyses. It also assesses activities of leading companies. Visiongain is a business information publisher and consultancy in London, UK. That company’s purpose is to help organisations research and analyse industries by showing technological and commercial prospects.

The new survey predicts expansion in the kidney cancer treatment market will cease between 2019 and 2024, owing to the expiration of patents on several leading renal cancer drug treatments, including Pfizer’s Sutent (sunitinib), Roche’s Avastin (bevacizumab), Novartis’ Votrient (pazopanib) and Bayer Healthcare and Onyx Pharmaceuticals’ Nexavar (sorafenib).

In 2014, the angiogenesis inhibitor submarket formed the most lucrative part of that industry, accounting for 69.8% of the overall world market. That segment, however, will lose a large percentage of market share to generics and other product classes owing to loss of patent protection affecting leading renal cancer drug revenues. The overall world market retains potential as it holds promising research and development. R&D involves innovative new therapies, especially in immunotherapy, which generate commercial interest. Those products include checkpoint inhibitors. Medicines in development can bring a new era for immunotherapy and make a difference in long-term treatment success for renal cancer patients.

Mashael Zaidi, a pharmaceutical industry analyst in visiongain, said:“The renal cancer treatment market has strong potential, with a R&D pipeline holding combination therapies, targeted therapies and novel areas of research. In particular, immunotherapies will impact the market and bring a new class of treatment to the market that may have better duration of response. This improvement in treatment will keep it from becoming a static market and these novel treatments will be needed to compensate for important patent expiries allowing for the entrance of strong generic competition. However, as treatments are costly, it is important for them to be deemed cost effective in order to keep pace with healthcare budgets, to be accessible. The market will continue to grow over the forecast period, bolstered by a growing incidence of renal cancer and a rise in ageing population that will ensure demand stays strong.”

Visiongain’s new investigation shows revenue forecasts to 2025 at overall world market, submarket, product and national level. It also analyses products in development.

First that study forecasts five subsectors of the renal cancer treatment market to 2025:

·         Angiogenesis inhibitors

·         mTOR inhibitors

·         Monoclonal antibodies (mAbs)

·         Immunotherapies

·         Generics and other products.

That report also breaks its revenue forecasting to 2025 into eight individual predictions for marketed renal cancer drugs:

·         Sutent (sunitinib)

·         Nexavar (sorafenib)

·         Votrient (pazopanib)

·         Inlyta (axitinib)

·         Afinitor (everolimus)

·         Torisel (temsirolimus)

·         Avastin (bevacizumab)

·         Proleukin (aldesleukin).

The new survey also analyses leading national markets for renal cancer treatment, showing revenue forecasts to 2025 for these 11 countries:

·         United States (US)

·         Japan

·         Germany, France, the United Kingdom (UK), Italy and Spain (EU5 group)

·         Brazil, Russia, India and China (BRIC countries).

Visiongain’s work examines leading pharmaceutical companies. That investigation discusses mergers and acquisitions, collaborations and R&D. Companies the report profiles include these leading organisations:

·         Pfizer

·         Novartis

·         Roche

·         Bayer Healthcare

·         Bristol-Myers Squibb.

Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services.